Laurence Leysen1,2, Astrid Lahousse2, Jo Nijs1,2,3, Nele Adriaenssens2,4, Olivier Mairesse5,6, Sergei Ivakhnov2, Thomas Bilterys1,2,7, Eveline Van Looveren1,7, Roselien Pas1,2, David Beckwée8,9. 1. Pain in Motion International Research Group. 2. Department of Physiotherapy, Human Physiology and Anatomy, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Building F-kine, Laarbeeklaan 103, 1090, Brussels, Belgium. 3. Department of Physical Medicine and Physiotherapy, University Hospital Brussels, Brussels, Belgium. 4. Department of Oncology, University Hospital Brussels, Brussels, Belgium. 5. Experimental and Applied Psychology, Faculty of Psychology and Educational Sciences, Vrije Universiteit Brussel, Brussels, Belgium. 6. Sleep Laboratory and Unit for Chronobiology, Brugmann University Hospital, Brussels, Belgium. 7. Department of Rehabilitation Sciences and Physiotherapy, Faculty of Medicine and Health Sciences, Ghent University, Campus Heymans, Building B3, Corneel Heymanslaan 10, 9000, Ghent, Belgium. 8. Department of Physiotherapy, Human Physiology and Anatomy, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Building F-kine, Laarbeeklaan 103, 1090, Brussels, Belgium. David.beckwee@vub.be. 9. Department of Rehabilitation Sciences and Physiotherapy, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium. David.beckwee@vub.be.
Abstract
BACKGROUND: Breast cancer remains the most frequently diagnosed malignancy among women worldwide, with rising incidence numbers. In Belgium, one out of eight women will be diagnosed with breast cancer. Fortunately, 80% of those breast cancer patients will still be alive 10 years after diagnosis due to improvements in screening and treatment strategies. However, an important portion of the breast cancer survivors (BCS) will face side effects, such as sleep disturbances, long after treatment ends. It has been demonstrated that untreated insomnia in BCS negatively impacts mood, physical symptoms, pain sensitivity, fatigue, and quality of life. Furthermore, insomnia is increasingly considered an independent risk factor for future depression in BCS. The importance of understanding sleep disturbances in cancer populations has been highlighted and recognized as warranting further research. Therefore, the purpose of this systematic review was to determine the prevalence and the risk factors for the development of sleep disturbances in BCS. METHODS: PubMed, Web of Science, and PEDro were systematically screened for studies encompassing data regarding the prevalence or risk factors of sleep disturbances in BCS. If possible, meta-analyses were performed. Subgroup analyses were undertaken based on the methodological quality, study design, type of sleep disturbance, and the use of a measurement tool with strong psychometric properties to investigate significant heterogeneity (I2 > 50%) across studies. RESULTS: A total of 27 studies were found eligible. The pooled estimate for sleep disturbances prevalence is 0.40 (95% confidence interval (CI) = [0.29-0.52], I2 = 100%, p < 0.00001) and ranged from 0.14 (95% CI = [0.04-0.24]) to 0.93 (95% CI = [0.91-0.95]). Subgroup analyses did not reduce the heterogeneity among studies. Meta-analyses were performed for seven risk factors. Significant differences for the odds of developing sleep disturbances were found for hot flashes (pooled OR (ORp) 2.25, 95% CI = [1.64-3.08], I2 = 0%, p = 0.90), race (ORp 2.31, 95% CI = [1.56-3.42], I2 = 0%, p = 0.47), and menopause (ORp 1.84, 95% CI = [1.11-3.06], I2 = 0%, p = 0.70). After withdrawing the studies that did not rely on the use of a measurement tool with strong psychometric properties, pain (ORp 2.31, 95% CI = [1.36-3.92], I2 = 27%, p = 0.25), depressive symptoms (ORp 3.20, 95% CI [2.32-4.42], I2 = 0%, p = 0.63), and fatigue (ORp 2.82, 95% CI = [1.98-4.02], I2 = 0%, p = 0.60) became significant as well, with a substantial decrease of heterogeneity. CONCLUSION: Prevalence for sleep disturbances ranged from 0.14 to 0.93 with the vast majority of the studies investigating insomnia and sleep-wake disturbances. High heterogeneity makes it difficult to draw firm conclusions. Pain, depressive symptoms, hot flashes, fatigue, non-Caucasian race, and menopausal status were significantly associated with increased odds for developing sleep disturbances.
BACKGROUND:Breast cancer remains the most frequently diagnosed malignancy among women worldwide, with rising incidence numbers. In Belgium, one out of eight women will be diagnosed with breast cancer. Fortunately, 80% of those breast cancerpatients will still be alive 10 years after diagnosis due to improvements in screening and treatment strategies. However, an important portion of the breast cancer survivors (BCS) will face side effects, such as sleep disturbances, long after treatment ends. It has been demonstrated that untreated insomnia in BCS negatively impacts mood, physical symptoms, pain sensitivity, fatigue, and quality of life. Furthermore, insomnia is increasingly considered an independent risk factor for future depression in BCS. The importance of understanding sleep disturbances in cancer populations has been highlighted and recognized as warranting further research. Therefore, the purpose of this systematic review was to determine the prevalence and the risk factors for the development of sleep disturbances in BCS. METHODS: PubMed, Web of Science, and PEDro were systematically screened for studies encompassing data regarding the prevalence or risk factors of sleep disturbances in BCS. If possible, meta-analyses were performed. Subgroup analyses were undertaken based on the methodological quality, study design, type of sleep disturbance, and the use of a measurement tool with strong psychometric properties to investigate significant heterogeneity (I2 > 50%) across studies. RESULTS: A total of 27 studies were found eligible. The pooled estimate for sleep disturbances prevalence is 0.40 (95% confidence interval (CI) = [0.29-0.52], I2 = 100%, p < 0.00001) and ranged from 0.14 (95% CI = [0.04-0.24]) to 0.93 (95% CI = [0.91-0.95]). Subgroup analyses did not reduce the heterogeneity among studies. Meta-analyses were performed for seven risk factors. Significant differences for the odds of developing sleep disturbances were found for hot flashes (pooled OR (ORp) 2.25, 95% CI = [1.64-3.08], I2 = 0%, p = 0.90), race (ORp 2.31, 95% CI = [1.56-3.42], I2 = 0%, p = 0.47), and menopause (ORp 1.84, 95% CI = [1.11-3.06], I2 = 0%, p = 0.70). After withdrawing the studies that did not rely on the use of a measurement tool with strong psychometric properties, pain (ORp 2.31, 95% CI = [1.36-3.92], I2 = 27%, p = 0.25), depressive symptoms (ORp 3.20, 95% CI [2.32-4.42], I2 = 0%, p = 0.63), and fatigue (ORp 2.82, 95% CI = [1.98-4.02], I2 = 0%, p = 0.60) became significant as well, with a substantial decrease of heterogeneity. CONCLUSION: Prevalence for sleep disturbances ranged from 0.14 to 0.93 with the vast majority of the studies investigating insomnia and sleep-wake disturbances. High heterogeneity makes it difficult to draw firm conclusions. Pain, depressive symptoms, hot flashes, fatigue, non-Caucasian race, and menopausal status were significantly associated with increased odds for developing sleep disturbances.
Entities:
Keywords:
Breast cancer survivors; Determinants; Insomnia; Prevalence; Risk factors; Sleep disturbances
Authors: Catherine M Alfano; Kenneth L Lichstein; Gregory S Vander Wal; Ashley Wilder Smith; Bryce B Reeve; Anne McTiernan; Leslie Bernstein; Kathy B Baumgartner; Rachel Ballard-Barbash Journal: Breast Cancer Res Treat Date: 2011-05-13 Impact factor: 4.872
Authors: Eun Sook Lee; Myung Kyung Lee; Soo Hyun Kim; Jung Sil Ro; Han Sung Kang; Seok Won Kim; Keun Seok Lee; Young Ho Yun Journal: Ann Surg Date: 2011-01 Impact factor: 12.969
Authors: Laura P Forsythe; Catherine M Alfano; Stephanie M George; Anne McTiernan; Kathy B Baumgartner; Leslie Bernstein; Rachel Ballard-Barbash Journal: Breast Cancer Res Treat Date: 2012-12-15 Impact factor: 4.872
Authors: Oxana G Palesh; Joseph A Roscoe; Karen M Mustian; Thomas Roth; Josée Savard; Sonia Ancoli-Israel; Charles Heckler; Jason Q Purnell; Michelle C Janelsins; Gary R Morrow Journal: J Clin Oncol Date: 2009-11-23 Impact factor: 44.544
Authors: Melissa L McPheeters; Sunil Kripalani; Neeraja B Peterson; Rachel T Idowu; Rebecca N Jerome; Shannon A Potter; Jeffrey C Andrews Journal: Evid Rep Technol Assess (Full Rep) Date: 2012-08
Authors: Michel P Coleman; Manuela Quaresma; Franco Berrino; Jean-Michel Lutz; Roberta De Angelis; Riccardo Capocaccia; Paolo Baili; Bernard Rachet; Gemma Gatta; Timo Hakulinen; Andrea Micheli; Milena Sant; Hannah K Weir; J Mark Elwood; Hideaki Tsukuma; Sergio Koifman; Gulnar Azevedo E Silva; Silvia Francisci; Mariano Santaquilani; Arduino Verdecchia; Hans H Storm; John L Young Journal: Lancet Oncol Date: 2008-07-17 Impact factor: 41.316
Authors: Ann Partridge; Shari Gelber; Richard D Gelber; Monica Castiglione-Gertsch; Aron Goldhirsch; Eric Winer Journal: Eur J Cancer Date: 2007-05-18 Impact factor: 9.162
Authors: Isamme AlFayyad; Mohamad Al-Tannir; Jude Howaidi; Dana AlTannir; Amani Abu-Shaheen Journal: Qual Life Res Date: 2022-04-30 Impact factor: 3.440
Authors: Meagan S Whisenant; Loretta A Williams; Tito Mendoza; Charles Cleeland; Tsun-Hsuan Chen; Michael J Fisch; Quiling Shi Journal: Cancer Nurs Date: 2021-12-28 Impact factor: 2.760
Authors: Susan Grayson; Susan Sereika; Caroline Harpel; Emilia Diego; Jennifer G Steiman; Priscilla F McAuliffe; Susan Wesmiller Journal: Support Care Cancer Date: 2021-07-10 Impact factor: 3.603
Authors: Diane K Ehlers; Jason Fanning; Alexis Sunderlage; Joan Severson; Arthur F Kramer; Edward McAuley Journal: Cancer Med Date: 2020-03-23 Impact factor: 4.452
Authors: Xian-Liang Liu; Hui Lin Cheng; Simon Moss; Carol Chunfeng Wang; Catherine Turner; Jing-Yu Tan Journal: Evid Based Complement Alternat Med Date: 2020-04-28 Impact factor: 2.629
Authors: Maha Mamoor; Michael A Postow; Jessica A Lavery; Shrujal S Baxi; Niloufer Khan; Jun J Mao; Lauren J Rogak; Robert Sidlow; Bridgette Thom; Jedd A Wolchok; Deborah Korenstein Journal: J Immunother Cancer Date: 2020-03 Impact factor: 13.751